Home

Alucent Biomedical has received US Food and Drug Administration (FDA) approval to proceed with a phase 1 clinical trial to evaluate the safety and efficacy of its Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral arterial disease (PAD) of the lower extremities, a condition that affects over 200 million people worldwide.

According to a press release, the Alucent NVS vessel restoration system with photoactivated linking combines standard angioplasty with linking of the structural proteins in the wall of a blood vessel. The intervention is designed to deliver immediate restoration of the vessel’s lumen and sustained improvement of blood flow, without the introduction of a foreign implant, such as a metallic stent, into the patient’s body. Because there is no rigid foreign material, the arterial wall has the potential to retain its natural functionality and flexibility, and avoid the complications of permanent stents. Alucent NVS photoactivated linking is also designed to mitigate the adverse effects of angioplasty, such as vessel recoil. Sustained, improved blood flow is expected to result in pain relief, limb preservation, and an improved quality of life for patients.

“FDA approval to commence human clinical testing allows us to move this revolutionary therapy into PAD patients, many of whom are in acute need of a better and more durable alternative to currently available treatments,” comments Myles Greenberg, CEO of Alucent.

Preclinical testing of NVS in animal studies has shown acute and long-term safety and patency without the pro-inflammatory and mechanical risks of placing a rigid foreign implant into the blood vessel.

“Alucent NVS is a novel and disruptive medical therapy that may promote better clinical outcomes in patients with symptomatic femoropopliteal atherosclerosis without the use of a metallic implant. Moreover, given the novel nature of this therapy, which in animal models was able to restore vessel wall architecture, it has the potential to dramatically improve quality of life in patients with peripheral arterial disease”, says Krishna Rocha-Singh, chief scientific officer at HSHS St John’s Prairie Heart Institute in Springfield, USA, and chief medical advisor of Alucent Biomedical.

Enrollment for the phase 1 clinical trial is expected to begin in Q1 2020. Up to 15 patients will be enrolled across five research sites, including the Cardiovascular Institute of the South in Houma, USA, and the Wellmont Hollston Valley Medical Center in Kingsport, USA.

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua google bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua twitter bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua MySpace bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua LinkedIn bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua stumbleupon bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua icio bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua digg bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Chia sẽ qua yahoo bài: FDA approval to proceed with natural vascular scaffolding clinical trial

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.